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Summary
Reduced growth hormone (GH) signaling has been consistently
associated with increased health and lifespan in various mouse
models. Here, we assessed GH secretion and its control in relation
with human familial longevity. We frequently sampled blood over
24 h in 19 middle-aged offspring of long-living families from the
Leiden Longevity Study together with 18 of their partners as
controls. Circulating GH concentrations were measured every
10 min and insulin-like growth factor 1 (IGF-1) and insulin-like
growth factor binding protein 3 (IGFBP3) every 4 h. Using decon-
volution analysis, we found that 24-h total GH secretion was 28%
lower (P = 0.04) in offspring [172 (128–216) mU L1] compared
with controls [238 (193–284) mU L1]. We used approximate
entropy (ApEn) to quantify the strength of feedback/feedforward
control of GH secretion. ApEn was lower (P = 0.001) in offspring
[0.45 (0.39–0.53)] compared with controls [0.66 (0.56–0.77)], indi-
cating tighter control of GH secretion. No significant differences
were observed in circulating levels of IGF-1 and IGFBP3 between
offspring and controls. In conclusion, GH secretion in human
familial longevity is characterized by diminished secretion rate and
more tight control. These data imply that the highly conserved GH
signaling pathway, which has been linked to longevity in animal
models, is also associated with human longevity.
Key words: approximate entropy; familial longevity; growth
hormone; hormone secretion; human; IGF-1.
Introduction
Genetic disruption of the insulin/insulin-like growth factor 1 (IGF-1)
signaling (IIS) pathway can delay aging and promote longevity in a wide
variety of species (Longo & Finch, 2003). In mammalian species, growth
hormone (GH) plays a pivotal role in the regulation of the IIS pathway
and mutations affecting GH action have consistently been shown to alter
lifespan (Bartke et al., 2013). Increased longevity in mice can be induced
by mutations that result in GH deficiency, including the Prop-1 and Pit-1
mutations that cause a combined GH, prolactin, and thyroid-stimulating
hormone deficiency, and by deletion of the GH-releasing hormone
receptor (Brown-Borg et al., 1996; Flurkey et al., 2001). Likewise,
mutations resulting in GH resistance, notably deletion of the GH
receptor, were also found to increase longevity (Coschigano et al.,
2000). Accordingly, transgenic mice that overexpress GH are short-lived
and show signs of accelerated aging (Wolf et al., 1993). Also in humans,
patients with active acromegaly, who have excessive pituitary GH
secretion, were found to have a reduced life expectancy (Orme et al.,
1998). The results from studies on the association of mutations in the GH
pathway that lead to dwarfism in humans with lifespan are contradictory
(Sattler, 2013). While Laron syndrome dwarfs with GH receptor gene
mutations were found to have relatively long lifespans with reduced risks
for cancer and diabetes, patients with untreated GH deficiency had
relatively short lifespans (Laron, 2002; Besson et al., 2003; Guevara-
Aguirre et al., 2011).
However, little is known about how more subtle differences in GH/
IGF-1 secretion would affect human longevity. Interestingly, female
centenarians were found to be enriched for rare mutations causing
slight IGF-1 resistance and resulting in a somewhat smaller stature
(Suh et al., 2008). Likewise, we previously observed that a combina-
tion of polymorphisms in the GH/IIS pathway, linked to smaller stature
in female octogenarians, was associated with better survival in old age
(van Heemst et al., 2005). However, to the best of our knowledge, no
study has assessed the association of human longevity with GH
secretion.
GH secretion by somatotrophic cells in the anterior lobe of the
pituitary gland is stimulated by growth hormone-releasing hormone
(GHRH) and inhibited by somatostatin, both produced by the hypotha-
lamus. GH exerts its functions by binding to GH receptors located on
tissue target cells. A key function of GH is to stimulate production of IGF-
1 by the liver, which subsequently inhibits GH secretion via negative
feedback. Circulating IGF-1 is mostly bound to binding proteins of which
insulin-like growth factor binding protein 3 (IGFBP3) is the most
abundant. The IGF-1/IGFBP3 molar ratio is considered an indicator of
IGF-1 bioavailability. In humans, many other tissues besides the liver
express GH receptors indicating that GH may exert effects independent
from IGF-1 (Florini et al., 1996; de Mello-Coelho et al., 1998; Arce et al.,
2013). GH is secreted in a basal (nonpulsatile) and pulsatile mode. The
feedback control by IGF-1, together with the feedforward control by
GHRH and somatostatin, tightly regulates GH secretion (Giustina &
Veldhuis, 1998). The strength of these control signals can be estimated
mathematically via calculation of the approximate entropy (ApEn)
(Veldhuis et al., 2001). Both GH secretion and the strength of the
feedforward and/or feedback signals were found to be negatively
influenced by age and BMI (Zadik et al., 1985; Veldhuis et al., 2011).
Interestingly, women had higher 24-h serum GH concentrations and
higher ApEn values than men, indicating weaker control of GH secretion
(Pincus et al., 1996). Furthermore, GH secretion is strongly associated
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with sleep, with the major GH pulse generally occurring shortly after
sleep onset (Takahash et al., 1968).
To identify determinants of human longevity, the Leiden Longevity
Study (LLS) included offspring of long-lived families that are enriched for
exceptional longevity and partners thereof, serving as a control group.
Indeed, offspring were found to have less age-related diseases and
reduced mortality compared with controls (Westendorp et al., 2009).
Previously, no differences were observed between offspring and controls
in circulating IGF-1 concentrations (Rozing et al., 2009). However, the
magnitude and control of GH secretion have not yet been studied in
human familial longevity. Therefore, we aim in this study to compare GH
secretion parameters and the strength of GH secretion control signals
between offspring of long-lived families and age-matched controls.
Results
Group characteristics
The group characteristics of offspring and controls are presented in
Table 1. Participants were selected on the basis of the age of their
parents. Consequently, the parents of the offspring were significantly
older (P = 0.01) than those of the controls. The groups of offspring and
controls were similar in age, height, body composition, fasting serum
glucose and insulin levels, and sleep parameters. Also the distribution of
men and women in both groups was similar.
GH concentration profiles over 24 h
Individual GH concentration profiles were first assessed by visual
inspection. As illustrated in Fig. S1 (Supporting information), which
comprises the 24-h GH concentration profiles of all 37 participants, we
observed a wide variation between individual 24-h GH profiles.
Moreover, due to the pulsatile manner in which GH is secreted, GH
concentrations within individual time series vary strongly over 24 h.
Therefore, deconvolution analysis was applied to compare specific
features of GH secretion between groups.
GH secretion parameters
Table 2 shows that the offspring of long-lived families had a mean (95%
CI) total GH secretion over 24 h of 172 (128–216) mU L1. This was
significantly lower (P = 0.04) compared with that of controls (238 (193–
284) mU L1). The geometric mean (95% CI) basal GH secretion in
offspring (14.5 (9.8–21.5) mU L1) was also lower (P = 0.03) compared
with that of controls (26.9 (17.9–40.4) mU L1). The pulsatile GH
secretion was not significantly different between groups. Results did not
change after additional adjustments for BMI or waist circumference (data
not shown). Slow half-life, the number of pulses, and the interpulse
regularity (Weibull gamma) were similar between offspring and controls.
Similar differences as found between offspring and controls were also
observed in men and women separately (data not shown).
Approximate entropy
Offspring of long-lived families had a significantly lower (P = 0.001)
Jack-knifed approximate entropy (JkApEn) than controls (Fig. 1). Fig-
ure 1 shows the individual JkApEn for all participants with the
(unadjusted) mean with standard error. When analyses were adjusted
for age and sex, the geometric mean (95% CI) JkApEn was 0.45 (0.39–
0.53) for offspring and 0.66 (0.56–0.77) for controls (P = 0.001). The
differences found between offspring and controls were also observed in
men and women separately. Male offspring had a geometric mean (95%
CI) JkApEn of 0.38 (0.29–0.48) and male controls of 0.53 (0.42–0.68)
(P = 0.05). The geometric mean (95% CI) JkApEn of female offspring
was significantly lower (P = 0.005) than that of female controls [0.53
(0.44–0.65) vs. 0.82 (0.67–1.01)]. Results did not materially change after
additional adjustments for BMI or waist circumference (data not shown).
IGF-1 and IGFBP3
Geometric mean (95% CI) circulating levels of IGF-1 were 14.2 (12.6–
15.9) nmol L1 in the offspring and 16.0 (14.2–18.0) nmol L1 in
controls, which was not significantly different (P = 0.14). Mean IGFBP3
was similar in both groups. The mean (95% CI) IGF-1/IGFBP3 molar ratio
was also not significantly different (P = 0.10) in offspring compared with
controls [0.128 (0.116–0.140) vs. 0.142 (0.130–0.155)].
Discussion
The two main findings of this study are that GH secretion is lower and
more tightly controlled in subjects enriched for familial longevity
compared with age-matched controls.
The observed association between reduced GH secretion and human
familial longevity is in line with experimental studies in mice, which
found that reduced GH action resulted in extended health and lifespans
(Brown-Borg et al., 1996; Coschigano et al., 2000; Flurkey et al., 2001).
Our results implicate the highly conserved GH/IGF-1 signaling pathway,
which has been linked to delayed aging and longevity in numerous
animal models, also in human longevity. The observed differences in GH
secretion between offspring and controls can probably not be explained
by a faster clearance of GH from the blood, as the slow half-life was
comparable between groups. Previous studies found that high approx-
imate entropy (ApEn) values are indicative for reduced strength of
feedforward and/or feedback signals on GH secretion. ApEn values were
elevated in patients with GH deficiency and in patients with an
inactivating defect of the GHRH receptor gene, compared to healthy
individuals (Roelfsema et al., 2001, 2002). Accordingly, we observed low
values of ApEn in the offspring, which are indicative of tighter control.
Various mechanisms may underlie the observed reduction in GH
secretion in the offspring, including (i) less stimulatory feedforward drive
by GHRH, (ii) increased inhibition by somatostatin, and (iii) increased
Table 1 Group characteristics of offspring of long-lived families and controls
Offspring n = 19 Controls n = 18 P-value
Male n (%) 10 (52.6) 10 (55.6) 0.86
Age (years)† 65.7 (5.6) 64.6 (4.9) 0.52
BMI (kg m2)‡ 24.8 (22.7–29.9) 25.1 (22.1–27.7) 0.83
Height (cm)‡ 175 (165–180) 175 (167–182) 0.73
Waist circumference (cm)‡ 94 (82–101) 94 (83–98) 0.75
Fasting glucose (mmol L1)† 4.9 (0.7) 4.8 (0.4) 0.65
Fasting insulin (mU L1) 4.6 (3.8–8.0) 5.9 (3.8–7.8) 0.92
Average hours of sleep (h) 7.4 (7.0–7.9) 7.4 (6.9–7.8) 0.81
Chronotype§ 3.0 (2.5–3.5) 3.1 (2.6–3.6) 0.68
Mean age of parents (years) 88.0 (82.5–93.5) 80.3 (74.6–84.1) 0.001
Unless indicated otherwise, data are presented as median with interquartile ranges.
†Data are presented as mean with standard deviation.
‡Data were not available for one male control subject due to technical problems.
§Scores ranging from 1 (extreme early type) to 7 (extreme late type).
Bold values indicate P ≤ 0.05.
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negative feedback of IGF-1. Veldhuis et al. (2001) showed that reduced
ApEn values can also be explained by any of these three occurrences.
Our current data do not allow us to discriminate between these
possibilities.
Although somatostatin and GHRH are found in the circulation, these
were not measured as it is unknown to what extent these reflect leakage
from the brain, or peripheral production. We did measure circulating
levels of IGF-1 and IGFBP3, and calculated IGF-1/IGFBP3 molar ratios. The
IGF-1/IGFBP3 molar ratio was not higher in the offspring than in the
controls. However, other important IGF-1 binding proteins were not
measured; thus, we cannot exclude the possibility that differences in IGF-
1 bioavailability between groups may exist. Altered GH secretion can also
be caused by regulators of GH secretion other than somatostatin, GHRH,
and IGF-1. Certain neuropeptides and neurotransmitters also influence
GH secretion, such as ghrelin from the stomach, which directly
stimulates the release of GH by the pituitary (Giustina & Veldhuis,
1998; Dimaraki & Jaffe, 2006).
Different explanations exist for the observed association of diminished
GH secretion and familial longevity. A first possibility is that GH is
associated with longevity via a reduction of circulating IGF-1. In contrast
to long-living model organisms in which besides GH action, IGF-1 levels
are reduced, IGF-1 levels were not significantly different between
groups, although these tended to be somewhat lower in the offspring.
Possibly, our study was underpowered to detect subtle differences in
circulating IGF-1 between groups. However, also in a much larger
sample of offspring and controls, we previously did not observe
differences in circulating IGF-1, nor in stature (Rozing et al., 2009).
Circulating IGF-1 is predominantly produced by the liver. However, many
tissues produce paracrine IGF-1 that does not contribute to circulating
IGF-1. Interestingly, in Ames dwarf mice with reduced GH secretion,
brain IGF-1 levels were elevated compared to control mice (Sun et al.,
2005). In the current study, data on tissue-specific IGF-1 are lacking.
Therefore, the possibility that paracrine IGF-1 is crucial in terms of
longevity control could not be addressed. It is also possible that GH is
associated with longevity independent of IGF-1. In support of this
hypothesis, the impact of disrupting GH signaling on longevity is larger
than the impact of disrupting IGF-1 signaling or events downstream
from IGF-1 receptors in experimental mice (Bartke, 2011). Also in
humans, many tissues besides the liver express GH receptors, and the
association between reduced GH and human familial longevity might be
caused by direct effects of GH on these tissues (Florini et al., 1996; de
Mello-Coelho et al., 1998; Arce et al., 2013). Lastly, it is possible that
GH secretion is not causally related to longevity, but rather a pleiotropic
side effect of upstream regulators that influence longevity via other
mechanisms. For example, in addition to inhibiting GH secretion,
somatostatin influences the secretion of other hormones and was found
to inhibit cell proliferation and induce apoptosis (Weckbecker et al.,
2003). Also GHRH was found to have pleotropic effects in the periphery,
mainly on tissue regeneration (Kiaris et al., 2011).
A strength of our study is that we sampled blood every 10 min
during 24 h. Therefore, we could study the somatotropic axis in detail.
We performed our study in the LLS, in which families are included
based on two proband nonagenarian siblings. A consequence of the
LLS study design is that the age range of the offspring varied from 52
to 76 years and GH profiles could not be obtained at young age.
Another limitation of this study design is that not every offspring might
be enriched for longevity, as possibly not all inherited the favorable
predisposition for longevity of their long-lived parent. This could
have diluted potential differences between offspring and controls. It is
also a limitation that this study was performed with a relatively small
sample size.
To conclude, we report for the first time that GH secretion is more
tightly controlled in the offspring of long-lived families than in controls.
We hypothesize that the offspring are therefore more efficient in
regulating the magnitude and the timing of GH secretion. Our data











































Fig. 1 Control of GH secretion in offspring
and controls, with lower jack-knifed
approximate entropy (JkApEn) indicating
tighter control. JkApEn of GH secretion of
offspring and controls in all subjects (A),
men (B) and women (C). Lines indicate
mean and standard error of the mean.
Analyzed by linear mixed model adjusted
for sex and age (A) or only age (B and C).
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Table 2 GH secretion parameters in offspring of long-lived families and controls
Offspring n = 19 Controls n = 18 P-value
Slow half-life (minutes) 16.2 (14.3–18.0) 15.2 (13.3–17.1) 0.46
Total secretion (mU L1 per 24 h) 172 (128–216) 238 (193–284) 0.04
Basal secretion (mU L1 per 24 h)† 14.5 (9.8–21.5) 26.9 (17.9–40.4) 0.03
Pulsatile secretion (mU L1 per 24 h) 151 (113–188) 191 (152–230) 0.14
Number of pulses (per 24 h)† 13.7 (12.1–15.5) 13.8 (12.1–15.7) 0.97
Interpulse regularity c (unitless) 1.3 (1.2–1.5) 1.5 (1.3–1.7) 0.26
Unless indicated otherwise, data are presented as mean with 95% confidence interval.
†Data are presented as geometric mean with 95% confidence interval. Analyzed by linear mixed model adjusted for sex and age.
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mechanism implicated in mammalian longevity. We hypothesize that
pleiotropic and possibly tissue-specific effects of reduced GH secretion
may favor human longevity. Future research should focus on dissecting




As described previously in more detail, the Leiden Longevity Study (LLS)
comprises 421 families with at least two long-lived Caucasian siblings
fulfilling the age criteria (men ≥89 years and women ≥91 years) without
selection on health or demographics (Westendorp et al., 2009). In the
Switchbox Leiden Study (protocol P11.116), we included 20 offspring of
nonagenarian LLS participants together with 18 partners of the
offspring as environmental and age-matched controls (Jansen et al.,
2015). All participants were middle-aged (52–76 years), had a stable
body mass index (BMI) between 18 and 34 kg m2, and women were
postmenopausal. Exclusion criteria were having chronic renal, hepatic or
endocrine disease, or using medication known to influence lipolysis,
thyroid function, glucose metabolism, GH or IGF-1 secretion and/or any
other hormonal axis. Moreover, participants were excluded based on
the presence of fasting plasma glucose >7 mmol L1, recent trans-
meridian flight, smoking addiction, or extreme diet therapies. To be able
to safely perform the 24-h blood sampling, other exclusion criteria were
difficulties to insert and maintain an intravenous catheter, anemia
(hemoglobin <7.1 mmol L1), and blood donation within the last
2 months. Based on information obtained via telephone questioning,
controls with a nonagenarian parent who had one or more nonage-
narian siblings were also excluded. The Switchbox Leiden Study was
approved by the Medical Ethical Committee of the Leiden University
Medical Centre and performed according to the Helsinki declaration. All
participants gave written informed consent for participation. For the
current study, we excluded one female offspring from the analyses
based on a combination of features that suggest a subtle form of GH
resistance. Her pulsatile GH secretion (539 mU L1) deviated more than
three standard deviations from the mean pulsatile secretion of the
women included (193 mU L1), while her height (158 cm) was
relatively short compared to the mean height of the women included
(165 cm).
Clinical protocol
Full details on the 24-h blood sampling procedure have been described
previously (Akintola et al., 2015). In short, a catheter was placed in a
vein of the forearm of the nondominant hand of the participant. Blood
sampling started around 09:00 h and every 10 min, 3.2 mL of blood
was collected. All participants were sampled in the same research room.
The participants received standardized feeding at three fixed times
during the day (between 09:00 h and 10:00 h, 12:00 h and 13:00 h,
and 18:00 h and 19:00 h), each consisting of 600 kcal Nutridrink
(Nutricia Advanced Medical Nutrition Zoetermeer, The Netherlands). No
naps were allowed during the day, and lights were switched off for
approximately 9 h (circa between 23:00 h and 08:00 h). Height and
weight were measured in the research center. Body mass index (BMI)
was calculated as weight (in kilograms) divided by the square of height
(in meters). Waist circumference was measured with a measuring tape
midway between the uppermost border of the iliac crest and the lower
border of the costal margin.
Assays
All measurements were performed at the Department of Clinical
Chemistry and Laboratory Medicine of the Leiden University Medical
Centre in The Netherlands, which is accredited according to CCKL
(National Coordination Committee for Quality Assurance for Health Care
Laboratories in The Netherlands). Laboratory measurements were
performed with fully automated equipment and diagnostics from Roche
Diagnostics (Almere, The Netherlands) and Siemens Healthcare diagnos-
tics (The Hague, The Netherlands). Human growth hormone (hGH) with
a molecular mass of 22 kDa was measured in serum samples using
Siemens reagents (catalog number L2KGRH2) and an IMMULITE 2000
Xpi Immunoassay system (Siemens Healthcare diagnostics). The detec-
tion limit was 0.15 mU L1, and the interassay coefficient of variation
(CV) ranged between 5.4% at 5.43 mU L1 and 7.2% at 25.0 mU L1.
The reference range for fasting GH is 0.15–7.25 mU L1. All samples
were measured with reagents from the same lot numbers, and for each
participant, all samples (one time series) were measured in the same
batch on the same day. IGF-1 (catalog number IS-3900) and IGFBP3
(catalog number IS-4400) were measured in six plasma EDTA samples
with 4 h intervals for each participant using an iSYS Immunoassay
system of ImmunoDiagnostic Systems (IDS GMBH, Frankfurt am Main,
Germany). The CV ranges for IGF-1 and IGFBP3 were 1.4–1.8% and 6.3–
7.3%, respectively. Insulin (catalog number L2KIN2) and glucose (catalog
number 11876899216) were analyzed in a fasting morning (around
8:30 h) serum sample; insulin (CV ranged between 3.2 and 7.7%) using
an IMMULITE 2000 Xpi Immunoassay system (Siemens Healthcare
diagnostics) and glucose (CV ranged between 0.9 and 3.0%) using
Hitachi Modular P800 (Roche Diagnostics). In the Netherlands, hGH and
IGF-1 test results are routinely harmonized using a national harmoniza-
tion protocol and a harmonization serum pool as described elsewhere
(Ross et al., 2014). This means that all hGH and IGF-1 results reported in
this study are multiplied with 1.02 and 1.13, respectively.
Deconvolution analysis
The 24-h GH concentration profiles were analyzed by validated
deconvolution analysis (Liu et al., 2009). By deconvolution analysis, a
GH concentration profile is decomposed into underlying secretory bursts,
basal secretion, elimination of previously secreted GH, and random
experimental variability. The algorithm in the software program MATLAB
(the Mathworks, Inc., Natick, MA) first detrends the data and normalizes
concentrations to numbers within the interval 0 to 1. Thereafter,
successive potential pulse-time sets, each containing one fewer burst,
were created by a smoothing process. Finally, a maximum-likelihood
expectation deconvolution method estimated all secretion and elimina-
tion rates simultaneously for each candidate pulse-time set. Outcome
parameters of main interest are basal (nonpulsatile) secretion, pulsatile
secretion, the sum of basal and pulsatile secretion (total secretion),
number of pulses per 24 h (secretory-burst frequency), interpulse
regularity (Weibull gamma), and slow half-life. Fast half-life was fixed
to 3.5 min, and slow half-life was estimated as unknown variable
between 8 and 22 min.
Approximate entropy
Approximate entropy (ApEn) is a scale- and model-independent statistic
that quantifies the regularity of consecutive time-series data (Pincus,
1991). ApEn has high sensitivity and specificity (both >90%) for analysis
of hormone concentration measurements over 24 h. Low ApEn values
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imply that the sequence of time-series data is regular and that it contains
many repetitive patterns, such as a sinus wave. High ApEn values
indicate greater irregularity and randomness. For hormonal data, ApEn
provides a direct barometer for the strength of the feedback system. In
neuro-endocrine time-series of a length of 50–300 data points,
m (window length) = 1 is preferred, and for lengths N ≥ 60, r (criterion
of similarity) should be set to the predetermined value of 20% of the
standard deviation (SD) of the individual subject time series (Pincus et al.,
1999). Therefore, normalized ApEn parameters of m = 1 and r = 20%
of the SD of the individual subject time series were used. Additionally,
we calculated the Jack-knifed ApEn (JkApEn), which is a rigorous and
objective cross-validation test that gives less bias in smaller samples than
regular ApEn and it is more applicable for hormone data (Meyfroidt
et al., 2010).
Chronotype and sleep
Data on sleep parameters were obtained using the Pittsburgh Sleep
Quality Index questionnaire (Buysse et al., 1989). Chronotype was
assessed using the Munich Chronotype questionnaire, with scores
ranging from 1 (extreme early type) to 7 (extreme late type) (Roenneberg
et al., 2003; Zavada et al., 2005).
Statistical analysis
Descriptive statistics were used to summarize the characteristics of study
groups. The nonparametric Median Test was used to assess differences
between offspring and controls in the variables that were not normally
distributed. Independent-samples t-test was used to assess differences
between offspring and controls in variables that were normally
distributed. GH secretion parameters were compared between offspring
and controls using linear regression adjusted for sex and age. Not
normally distributed parameters were logarithmic transformed prior to
analysis and are presented as geometric means with 95% confidence
intervals. P ≤ 0.05 was considered statistically significant. All statistical
analyses were performed with SPSS for Windows, version 20 (SPSS,
Chicago, IL, USA). Graphs were made using GraphPad Prism version 6
(GraphPad, San Diego, CA, USA).
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